Faricimab can reduce vascular leakage and inflammation in patients who demonstrated a poor response to other anti-VEGF agents.

1月30日，罗氏公布2024年全年业绩，总营收达604.95亿瑞士法郎(约688.92亿美元)，同比增长7%(按固定汇率计算)。其中，制药业务 ...

典型的双抗药物如罗氏的Hemlibra（艾美赛珠单抗）、Vabysmo（Faricimab）等，不仅在国际市场上取得了卓越的成绩，甚至在中国市场也展示出强劲的增长态势。2018年，Hemlibra成为国内首款上市的双特异性抗体药物，其全球销售额在2023年达到了49.3亿美元，蕴含着巨大 ...

The following is a summary of “HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN,” published in the ...

Video content above is prompted by the following: As treatments with greater durability emerge, how might they change your approach to treating neovascular age-related macular degeneration or diabetic ...

Hoffmann-La Roche, and Teva. Clinic capacity constraints are an ever-increasing problem in ophthalmology. Multiple case studies demonstrate that faricimab frees up clinic capacity with extended ...

Various anti-VEGF agents are administered by intravitreal injections such as faricimab, bevacizumab, brolucizumab, aflibercept, and ranibizumab. The gene & cell therapy segment is expected to register ...